))
Experimental Elacestrant: A Standard of Care for Pre-Treated, Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer?
Manage episode 365353006 series 3482052
Breastcancer.org에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Breastcancer.org 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Dr. Aditya Bardia is associate professor of medicine at Harvard Medical School and director of the breast cancer research program at Massachusetts General Hospital Cancer Center.
At the 2021 San Antonio Breast Cancer Symposium, he presented results from the EMERALD trial, comparing the experimental medicine elacestrant to the standard of care for post-menopausal women diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy. That standard of care is either Faslodex or an aromatase inhibitor.
Listen to the podcast to hear Dr. Bardia explain:
- how elacestrant works
- the results of the EMERALD study
- what the results mean for post-menopausal women and men diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that has grown while being treated with hormonal therapy
348 에피소드
공유
